Study to Evaluate DNL201 in Subjects With Parkinson's Disease
Status:
Completed
Trial end date:
2019-12-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.